Transforming breast care.
We apply cutting-edge science to accelerate discovery, improve efficiency and continually sharpen precision.
For women facing breast cancer, Hologic is there from screening through treatment with technologies that advance early detection and the highest quality interventional products when necessary.
Our Genius 3D™ Mammography™ exam,* offered through our Selenia® Dimensions® system, finds 20%-65% more invasive breast cancers compared to 2D alone.1 It also reduces callbacks by up to 40% compared to 2D alone.2 Along with our other products, it reflects our ongoing drive to introduce innovations that bring greater certainty and peace of mind to both patients and the healthcare professionals who care for them.
* The Genius™ 3D Mammography™ exam (a.k.a. Genius™ exam) is acquired on the Hologic® 3D Mammography™ system and consists of a 2D and 3D™ image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D™ image set.
The Genius™ exam is only available on the Hologic® 3D Mammography™ system.
Please consult your physician for a full list of benefits and risks associated with mammography.
References: 1. Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20%-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1,000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ system versus women receiving 2D FFDM mammograms only. 2. Bernardi D, Macaskill P, Pellegrini M, et al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.